Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 5,059 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Capsule 2 Clear all

Conditions: Healthy
Interventions: LY4065967 Tablet, LY4065967 Formulated Capsule, LY4065967 Capsule; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Daytona Beach, Florida • Dallas, Texas

Conditions: Glioblastoma Multiforme, Adult
Interventions: Berubicin, Lomustine; Drug
Lead sponsor: CNS Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 32
States / cities: Little Rock, Arkansas • Los Angeles, California • Orange, California + 28 more

Conditions: Marijuana Dependence
Interventions: Vilazodone, Placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Healthy
Interventions: Buprenorphine / Naloxone; Drug
Lead sponsor: NanoSHIFT LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Ototoxicity, Drug-Induced
Interventions: ORC-13661, Placebo; Drug
Lead sponsor: Kevin Winthrop; Other
Eligibility: 18 Years to 80 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: San Francisco, California • Denver, Colorado • Baltimore, Maryland + 5 more

Conditions: Influenza A Virus
Interventions: JNJ-63623872, Placebo, Oseltamivir; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 14
States / cities: Fresno, California • Long Beach, California • Stanford, California + 11 more

Conditions: Generalized Anxiety Disorder
Interventions: Chamomile Extract, Placebo; Dietary Supplement · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Polycystic Ovary Syndrome, Insulin Resistance
Interventions: Cinnamon Supplementation, Placebo (wheat flour); Dietary Supplement
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 20 Years to 40 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Multiple Sclerosis
Interventions: Progressive exercise, Neuromuscular electrical stimulation delivered using the electrical therapy device EMPI 300 PV, Modified paleolithic diet, Omega 3 fatty acids, Full Spectrum vitamin, Essential - hydroxytyrosol, Maltodextrin fiber supplement, Mineral boost (magnesium), Niacinamide, Methyl B12, Taurine, creatine, thiamine, riboflavin, N acetylcysteine, alpha lipoic acid, L acetyl carnitine, methyl folate, coenzyme Q, meditation, self massage, learning, Coconut oil; Other · Device · Dietary Supplement + 1 more
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Non-alcoholic Steatohepatitis (NASH)
Interventions: ECC4703, Placebo; Drug
Lead sponsor: Eccogene; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Pharmacokinetics, Safety, Food-drug Interaction
Interventions: 200 mg resveratrol as JOTROL, 500 mg resveratrol as JOTROL, 700 mg resveratrol as JOTROL, 500 mg resveratrol as JOTROL administered to assess influence of food; Drug
Lead sponsor: Jupiter Orphan Therapeutics Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Obesity
Interventions: Oral Azelaprag (BGE-105), Oral Placebo for Azelaprag (BGE-105), Tirzepatide, Tirzepatide Placebo; Drug
Lead sponsor: BioAge Labs, Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 14
States / cities: Mesa, Arizona • Los Angeles, California • Montclair, California + 11 more

Conditions: Inclusion Body Myositis
Interventions: Arimoclomol; Drug
Lead sponsor: ZevraDenmark; Industry
Eligibility: 45 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 11
States / cities: Phoenix, Arizona • Irvine, California • Aurora, Colorado + 8 more

Conditions: Stage IV Non-small Cell Lung Cancer
Interventions: Antineoplaston therapy (Atengenal + Astugenal); Drug
Lead sponsor: Burzynski Research Institute; Other
Eligibility: 18 Years to 99 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 1998
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Berberine, Sprint Training, Wellbeing, Anaerobic Power, Inflammation Biomarkers, Monocyte Function
Interventions: Berberine, Placebo, Sprint Interval Training; Dietary Supplement · Other
Lead sponsor: University of Northern Colorado; Other
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Greeley, Colorado

Conditions: Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
Interventions: ORX750, Placebo; Drug
Lead sponsor: Centessa Pharmaceuticals (UK) Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 29
States / cities: Auburn, Alabama • Chandler, Arizona • Scottsdale, Arizona + 24 more

Conditions: Endometriosis, Endometriosis Related Pain, Endometriosis, Pain
Interventions: Dronabinol Capsules, Placebo; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 64 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Hosuton, Texas • Houston, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: JNJ-38431055, Sitagliptin 100 mg, JNJ-38431055 + Sitagliptin 100 mg, Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Diabetes Mellitus, Type 2
Interventions: TAK-875, Glimepiride, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 64
States / cities: Birmingham, Alabama • Hoover, Alabama • Tucson, Arizona + 61 more

Conditions: Low Back Pain
Interventions: Naproxen, Placebo, Diazepam; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 21 Years to 69 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Tardive Dyskinesia (TD)
Interventions: Valbenazine, Placebo oral capsule; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 42
States / cities: Little Rock, Arkansas • Anaheim, California • Costa Mesa, California + 35 more

Conditions: HIV Infections, Hepatitis C, Liver Disease
Interventions: Peginterferon alfa-2a, Ribavirin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 36
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 23 more

Conditions: Advanced Malignancies
Interventions: Alisertib; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Knee Osteoarthristis
Interventions: NRPT; Dietary Supplement
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: San Diego, California

Search by objective public record fields.

A Study of LY4065967 in Healthy Participants

A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

Vilazodone Treatment for Marijuana Dependence

A Single-Dose Study of an Investigational Capsule Formulation of 2 mg/0.5 mg Buprenorphine/Naloxone

Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin

A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A Infection

Chamomile Therapy for Generalized Anxiety

Effect of Cinnamon Extract on Insulin Resistance in Polycystic Ovary Syndrome

Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)

FTIH of ECC4703 in Healthy Volunteers

JOTROL PK, Safety, and Food Effect Assessment

Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over

Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial

Antineoplaston Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Berberine Supplementation, Sprint Interval Training, and Immune Function Study

A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia

Dronabinol As an Adjunct for Reducing Pain (DARP)-Texas Children's Hospital

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Doses of JNJ-38431055, Sitagliptin, and Co-administration of JNJ-38431055 and Sitagliptin

Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus

Diazepam Use With Standard Management for Acute Low Back Pain

Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia

Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)

A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors

Study NRPT Feasibility in Knee Osteoarthritis